Cyclophosphamide
Pancreatic Neuroendocrine Tumor
Explore 33 assets in Pancreatic Neuroendocrine Tumor →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Anusha Kalbasi
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04119024CT.gov Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neuroendocrine Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Anusha Kalbasi | P1 | CC · 41 |
| Oxodotreotide | University of Chicago | P4 | BBB |
| Everolimus | Exelixis | P4 | BBB |
| Irinotecan | M.D. Anderson Cancer Center | P2/3 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | RayzeBio, Inc. | P3 | BB |
| Capecitabine | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BB |
| Zanzalintinib | Exelixis | P3 | BB |
| Fluorouracilum | H. Lee Moffitt Cancer Center and Research Institute | P2/3 | BB |
| Sapanisertib | National Cancer Institute (NCI) | P2 | B |
+41 more in the Pancreatic Neuroendocrine Tumor cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OxodotreotideUniversity of ChicagoBBB
- EverolimusExelixisBBB
- IrinotecanM.D. Anderson Cancer CenterBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-RayzeBio, Inc.BB
- CapecitabineGustave Roussy, Cancer Campus, Grand ParisBB
Citation
Floatz Terminal. Cyclophosphamide in Pancreatic Neuroendocrine Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-pancreatic-neuroendocrine-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →